Literature DB >> 9491146

Phase III randomized comparison of postoperative adjuvant chemotherapy with 2-year oral UFT (uracil/tegafur) versus six-cycle CMF (cyclophosphamide/methotrexate/5-fluorouracil) in high-risk node-negative breast cancer patients.

T Watanabe1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9491146     DOI： 10.1093/jjco/28.1.77

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN： 0368-2811            Impact factor:   3.019


× No keyword cloud information.
  2 in total

Review 1.  UFT (tegafur and uracil) as postoperative adjuvant chemotherapy for solid tumors (carcinoma of the lung, stomach, colon/rectum, and breast): clinical evidence, mechanism of action, and future direction.

Authors:  Fumihiro Tanaka
Journal:  Surg Today       Date:  2007-10-25       Impact factor: 2.549

2.  Validation of a nuclear grading system for resected stage I-IIIA, high-risk, node-negative invasive breast carcinoma in the N·SAS-BC 01 trial.

Authors:  Hitoshi Tsuda; Masafumi Kurosumi; Futoshi Akiyama; Shinji Ohno; Shigehira Saji; Norikazu Masuda; Akihiko Shimomura; Nobuaki Sato; Shintaro Takao; Shozo Ohsumi; Yutaka Tokuda; Hideo Inaji; Toru Watanabe
Journal:  Breast Cancer       Date:  2022-04-18       Impact factor: 3.307
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.